BMY vs IBRX
BMY: A leading biopharmaceutical innovator focused on discovering and delivering life-changing medicines to address serious illnesses globally. IBRX: ImmunityBio develops innovative immunotherapies and cell-based cancer vaccines that leverage its Cancer BioShield platform to treat oncology and infectious disease patients.
Side-by-side fundamentals
| Metric | BMY | IBRX | Edge |
|---|---|---|---|
| Price as of 2026-08-11 close | $63.61 | $7.60 | |
| Market cap as of 2026-08-12 | $129.9B | $8.1B | |
| P/E as of 2026-08-12 | 14.29 | n/a | |
| PEG as of 2026-08-12 | -8.67 | -0.08 | BMY lower |
| Net margin as of 2026-08-12 | +18.9% | -598.6% | BMY higher |
| Gross margin as of 2026-08-12 | +71.7% | +99.3% | IBRX higher |
| Operating margin as of 2026-08-12 | +25.5% | -151.9% | BMY higher |
| ROE as of 2026-08-12 | +46.8% | -193.3% | BMY higher |
| ROA as of 2026-08-12 | +10.3% | -172.9% | BMY higher |
| Debt / equity as of 2026-08-12 | 1.93 | 0.00 | IBRX lower |
| Revenue growth (YoY) as of 2026-08-12 | +3.1% | +192.9% | IBRX higher |
| Revenue CAGR (3y) SEC XBRL | +1.4% | +678.6% | IBRX higher |
| Dividend yield as of 2026-08-12 | +3.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-12 | 0.17 | 0.07 | |
| 1-year return as of 2026-08-11 close | +38.5% | +207.7% | IBRX higher |
Fundamentals: market data, as of 2026-08-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-11.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.